To determine whether mTORC1 mediates AdPLA2 upregulation, rapamycin treatment was employed in Tsc2−/−p53−/− and Tsc2+/+p53−/− MEFs [33], Tsc2-deficient [32], [37] and TSC2-addback [38] rat uterine-leiomyoma-derived ELT3 cells, and TSC2-deficient LAM patient-derived cells [29]. This evidence concerns the gene TSC2 and lymphangioleiomyomatosis.